Action of fluoroquinolones and linezolid on logarithmic- and stationary-phase culture of Mycobacterium tuberculosis

Chemotherapy

Volumn 50, Issue 5, 2004, Pages 211-213

  Garcia Tapia A ^a   Rodriguez J C ^a   Ruiz, M ^a   Royo, G ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

Author keywords

Fluoroquinolones; Linezolid; Mycobacterium tuberculosis

Indexed keywords

GATIFLOXACIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; CONTROLLED STUDY; DISEASE COURSE; DRUG ACTIVITY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS;

ACETAMIDES; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; CULTURE MEDIA; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HYDROGEN-ION CONCENTRATION; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; OFLOXACIN; OXAZOLIDINONES; QUINOLINES; RIFAMPIN; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS;

EID: 9144271376     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081707     Document Type: Article

References (33)

1. Stokstad E: Infectious disease. Drug-resistant TB on the rise. Science 2000;287:2391.
2. Iseman MD: Treatment and implications of multidrug-resistant tuberculosis for the 21st century. Chemotherapy 1999;45(suppl 2):34-40.
3. Maranetra KN: Quinolones and multidrug-resistant tuberculosis. Chemotherapy 1999; 45(suppl 2):12-18.
4. Iseman MD: Management of multidrug-resistant tuberculosis. Chemotherapy 1999;45(suppl 2):3-11.
5. Rodríguez JC, Ruiz M, Climent A, Royo G: In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis. Int J Antimicrob Agents 2001;17:229-231.
6. Fung-Tomc J, Minassian B, Kolek B, Washo T, Huczko E, Bonner D: In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin. J Antimicrob Chemother 2000;45:437-446.
7. Renau TE, Gage JW, Dever JA, et al: Structure-activity relationships of quinolone agents against mycobacteria: Effect of structural modifications at the 8 position. Antimicrob Agents Chemother 1996;10:2363-2368.
8. Rodríguez JC, Ruiz, M, López M, Royo G: In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int J Antimicrob Agents 2002;20:464-467.
9. 2+ levels. Infect Immun 2000;68:4518-4522.
10. Wickelgren I: New clues to how the TB bacillus persists. Science 2000;288:1314-1315.
11. Bishai WR: Rekindling old controversy on elusive lair of latent tuberculosis. Lancet 2000; 356:2113-2114.
12. McKinney JD, Honer zu Bentrup K, Munoz-Elias EJ, et al: Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 2000;406:735-738.
13. Flynn JL, Chan J: Tuberculosis: Latency and reactivation. Infect Immun 2001;69:4195-4201.
14. Murugasu-Oei B, Dick T: Bactericidal activity of nitrofurans against growing and dormant Mycobacterium bovis BCG. J Antimicrob Chemother 2000;46:917-919.
15. Wayne LG, Sramek HA: Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1994;38:2054-2058.
16. Hernandez-Pando R, Jeyanathan M, Mengistu G, et al: Persistence of DNA from Mycobacterium tuberculosis in superficially normal lung tissue during latent infection. Lancet 2000;356:2133-2138.
17. Zurenko GE, Yagi BH, Schaadt RD, et al: In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996;40:839-845.
18. Barbachyn MR, Hutchinson DK, Brickner SJ, et al: Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity. J Med Chem 1996;39:680-685.
19. Ashtekar DR, Costa-Periera R, Shrinivasan T, Iyyer R, Vishvanathan N, Rittel W: Oxazolidinones, a new class of synthetic antituberculosis agent. In vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis. Diagn Microbiol Infect Dis 1991;14:465-471.
20. Cynamon MH, Klemens SP, Sharpe CA, Chase S: Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother 1999;43:1189-1191.
21. Valencia ME, Moreno V, Laguna F, González-Lahoz JM: Tuberculosis multirresistente por Mycobacterium bovis e infección por el virus de la inmunodeficiencia humana. ¿Existen nuevas posibilidades terapéuticas? Enferm Infecc Microbiol Clín 2001;19:37-39.
22. Yew WW, Chan CK, Chau CH, et al: Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin- containing regimens. Chest 2000;117:744-751.
23. Singla R, Gupta S, Gupta R, Arora VK: Efficacy and safety of sparfloxacin in combination with kanamycin and ethionamide in multidrug-resistant pulmonary tuberculosis patients: Preliminary results. Int J Tuberc Lung Dis 2001;5:559-563.
24. Berning SE: The role of fluoroquinolones in tuberculosis today. Drugs 2001;61:9-18.
25. Wallis RS, Palaci M, Vinhas S, et al: A whole blood bactericidal assay for tuberculosis. J Infect Dis 2001;183:1300-1303.
26. Yoshimatsu T, Nuermberger E, Tyagi S, Chaisson R, Bishai W, Grosset J: Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis. Antimicrob Agents Chemother 2002;46:1875-1879.
27. Ji B, Lounis N, Maslo C, Truffot-Pernot C, Bonnafous P, Grosset J: In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998;42:2066-2069.
28. Alvirez-Freites EJ, Carter JL, Cynamon MH: In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2002;46:1022-1025.
29. Herbert D, Paramasivan CN, Venkatesan P, Kubendiran G, Prabhakar R, Mitchison DA: Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic-and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996;40:2296-2299.
30. Dong Y, Zhao X, Kreiswirth BN, Drlica K: Mutant prevention concentration as a measure of antibiotic potency: Studies with clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2000;44:2581-2584.
31. Zhou J, Dong Y, Zhao X, et al: Selection of antibiotic-resistant bacterial mutants: Allelic diversity among fluoroquinolone-resistant mutations. J Infect Dis 2000;182:517-525.
32. Ziv E, Daley CL, Blower SM: Early therapy for latent tuberculosis infection. Am J Epidemiol 2001;153:381-385.
33. Dick T: Dormant tubercle bacilli: The key to more effective TB chemotherapy? J Antimicrob Chemother 2001;47:117-118.